TY  - JOUR
AU  - Zheng, Ziwen
AU  - Wieder, Thomas
AU  - Mauerer, Bernhard
AU  - Schäfer, Luisa
AU  - Kesselring, Rebecca
AU  - Braumüller, Heidi
TI  - T Cells in Colorectal Cancer: Unravelling the Function of Different T Cell Subsets in the Tumor Microenvironment.
JO  - International journal of molecular sciences
VL  - 24
IS  - 14
SN  - 1422-0067
CY  - Basel
PB  - Molecular Diversity Preservation International
M1  - DKFZ-2023-01539
SP  - 11673
PY  - 2023
AB  - Therapeutic options for metastatic colorectal cancer (mCRC) are very limited, and the prognosis using combination therapy with a chemotherapeutic drug and a targeted agent, e.g., epidermal growth factor receptor or tyrosine kinase, remains poor. Therefore, mCRC is associated with a poor median overall survival (mOS) of only 25-30 months. Current immunotherapies with checkpoint inhibitor blockade (ICB) have led to a substantial change in the treatment of several cancers, such as melanoma and non-small cell lung cancer. In CRC, ICB has only limited effects, except in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors, which comprise about 15
KW  - NKT cells (Other)
KW  - T cell therapy (Other)
KW  - colorectal cancer (Other)
KW  - immune checkpoint blockade (Other)
KW  - immunoscore (Other)
KW  - tumor-infiltrating T cells (Other)
KW  - αβ T cells (Other)
KW  - γδ T cells (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37511431
C2  - pmc:PMC10380781
DO  - DOI:10.3390/ijms241411673
UR  - https://inrepo02.dkfz.de/record/277871
ER  -